Editas Slims Down To Focus On Gene-Editing Sickle Cell Therapy Race
Needs To Catch Up With Two Rivals
Editas is seen as a slow developer in the CRISPR-based therapeutics field compared with its rivals but its new CEO has unveiled a new strategy to speed progress.
